Oncologic and Surgical Outcomes of Robotic Versus Open Radical Hysterectomy for Cervical Cancer.


Journal

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
ISSN: 1701-2163
Titre abrégé: J Obstet Gynaecol Can
Pays: Netherlands
ID NLM: 101126664

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 31 07 2018
revised: 14 09 2018
pubmed: 12 12 2018
medline: 29 7 2020
entrez: 12 12 2018
Statut: ppublish

Résumé

In view of the recent controversy concerning the use of minimally invasive radical hysterectomy as primary treatment for early stage cervical cancer, this study compared the survival and perioperative outcomes in a cohort of patients who underwent radical hysterectomy either by laparotomy or by robotics. This retrospective study compared all consecutive patients with early stage cervical cancer since the beginning of the Division of Gynecologic Oncology at the Jewish General Hospital in 2003, who underwent robotic radical hysterectomy (n = 74) with a cohort of all consecutive patients from the immediate past who underwent open radical hysterectomy (n = 24) for early stage cervical cancer. All patients were treated at the Jewish General Hospital in Montréal (Canadian Task Force Classification II-2). The median follow-up time for the robotic group was 46 months. During that time, 7% and 17% of patients in the robotic group and the laparotomy group had disease recurrence, respectively (P = 0.12). Cox multivariate regression showed no statistically significant effect of surgical approach on overall survival (hazard ratio 1.50, P = 0.63) or on progression-free survival (hazard ratio 0.29, P = 0.07). Patients in the robotic cohort had significantly shorter median hospital stays (1 day vs. 7 days, P < 0.001), and their overall incidence of postoperative complications was lower (13% vs. 50%, P < 0.001). Median estimated blood loss for robotics was also significantly lower (82 mL vs. 528 mL, P < 0.001). Based on the data on a limited number of patients in a Canadian context, robotic radical hysterectomy did not lead to worse oncologic outcomes and was associated with improved short-term surgical outcomes. One might consider the evaluation of more personalized surgical decision making.

Identifiants

pubmed: 30529223
pii: S1701-2163(18)30755-2
doi: 10.1016/j.jogc.2018.09.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

450-458

Informations de copyright

Copyright © 2018 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.

Auteurs

Emad Matanes (E)

Division of Gynecologic Oncology, Segal Cancer Centre, Lady Davis Institute of Research, Jewish General Hospital, McGill University, Montreal, QC.

Jeremie Abitbol (J)

Division of Gynecologic Oncology, Segal Cancer Centre, Lady Davis Institute of Research, Jewish General Hospital, McGill University, Montreal, QC.

Roy Kessous (R)

Division of Gynecologic Oncology, Segal Cancer Centre, Lady Davis Institute of Research, Jewish General Hospital, McGill University, Montreal, QC.

Liron Kogan (L)

Division of Gynecologic Oncology, Segal Cancer Centre, Lady Davis Institute of Research, Jewish General Hospital, McGill University, Montreal, QC.

David Octeau (D)

Division of Gynecologic Oncology, Segal Cancer Centre, Lady Davis Institute of Research, Jewish General Hospital, McGill University, Montreal, QC.

Susie Lau (S)

Division of Gynecologic Oncology, Segal Cancer Centre, Lady Davis Institute of Research, Jewish General Hospital, McGill University, Montreal, QC.

Shannon Salvador (S)

Division of Gynecologic Oncology, Segal Cancer Centre, Lady Davis Institute of Research, Jewish General Hospital, McGill University, Montreal, QC.

Walter H Gotlieb (WH)

Division of Gynecologic Oncology, Segal Cancer Centre, Lady Davis Institute of Research, Jewish General Hospital, McGill University, Montreal, QC. Electronic address: walter.gotlieb@mcgill.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH